Ocunexus   Report issue

For profit Phase 2
Founded: San Diego CA United States (2005)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2008
NCT00654550
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

CoDa Therapeutics Inc. | OcuNexus Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

nexagon (8 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Foot (Phase 2)

Foot Ulcer (Phase 2)

Leg Ulcer (Phase 2)

Ulcer (Phase 2)

Varicose Ulcer (Phase 2)

Wounds and Injuries (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 1